Prairie Education & Research Cooperative Joins MedNet Solutions' iMedNet CRO Partner Program
Minnetonka, MN – MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, and Prairie Education & Research Cooperative (PERC), an organization specializing in cardiovascular and vascular trial management, core lab, and continuing medical education services, are pleased to announce that PERC has joined the iMedNetTM CRO Partner Program. PERC will leverage iMedNet EDC, MedNet’s innovative cloud‐based eClinical technology platform, to easily and cost‐effectively build and manage their customers’ clinical research studies.
“iMedNet EDC provides an ideal electronic data capture solution that is financially feasible for PERC’s budget sensitive companies while maintaining a high level of functionality and flexibility,” stated Cynthia Deitrick, Chief Operating Officer at PERC. “PERC looks forward to future business opportunities where iMedNet can be utilized as a seamless solution for clinical trial sponsors.”
“MedNet is honored to be working with PERC-a top quality, highly‐respected clinical services organization,” noted Brian Sweeney, Vice President of Business Development at MedNet Solutions. “We’re confident that iMedNet EDC will provide the effective and reliable technology infrastructure they need for years to come.”
Please contact MedNet Solutions for more information on iMedNet EDC or the iMedNet CRO Partner Program, and PERC for additional details on their cardiovascular and vascular clinical services.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
